background common pathological feature chronic inflammatory airway diseases asthma chronic obstructive pulmonary disease copd mucus hypersecretion muc5ac predominant mucin gene expressed healthy airways increased asthmatic copd patients recent clinical trials indicate phosphodiesterase type NUMBER pde4 inhibitors therapeutic value copd asthma direct effects mucin expression scarcely investigated methods muc5ac mrna protein expression examined cultured human airway epithelial cells a549 human isolated bronchial tissue stimulated epidermal growth factor egf NUMBER muc5ac mrna measured real time muc5ac protein elisa cell lysates tissue homogenates western blotting tissue homogenates immunohistochemistry results egf increased muc5ac mrna protein expression a549 cells pde4 inhibitors produced concentration dependent inhibition egf induced muc5ac mrna protein expression potency values ic50 roflumilast approximately NUMBER rolipram approximately NUMBER cilomilast approximately NUMBER roflumilast inhibited egf induced expression phosphotyrosine proteins egf receptor measured western blot analysis a549 cells human isolated bronchus egf induced muc5ac mrna protein expression inhibited roflumilast NUMBER microm muc5ac positive staining shown immunohistochemistry conclusion selective pde4 inhibition effective decreasing egf induced muc5ac expression human airway epithelial cells effect contribute clinical efficacy new drug category mucus hypersecretory diseases rt pcr log phospho p38 mapk ng ml p44 NUMBER